Rigel Pharmaceuticals Files Q1 2025 10-Q
Ticker: RIGL · Form: 10-Q · Filed: May 6, 2025 · CIK: 1034842
| Field | Detail |
|---|---|
| Company | Rigel Pharmaceuticals Inc (RIGL) |
| Form Type | 10-Q |
| Filed Date | May 6, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals
Related Tickers: RIGL
TL;DR
Rigel Pharma dropped its Q1 2025 10-Q. Check financials.
AI Summary
Rigel Pharmaceuticals Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first quarter of 2025. Key financial figures and business developments are presented within this report.
Why It Matters
This filing provides investors with the latest financial health and operational status of Rigel Pharmaceuticals, crucial for understanding its current market position and future prospects.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Rigel faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2025-03-31 — Period End Date (Financial reporting period)
- 2025-01-01 — Period Start Date (Financial reporting period)
- 2024-03-31 — Prior Year Period End Date (Comparison period)
Key Players & Entities
- RIGEL PHARMACEUTICALS INC (company) — Filer
- 0001034842 (company) — Central Index Key
- 20250331 (date) — Period of Report
- 20250506 (date) — Filed as of Date
- 611 GATEWAY BOULEVARD, SUITE 900 (address) — Business Address
- SOUTH SAN FRANCISCO (location) — Business City
- 94080 (zip_code) — Business Zip
- 650-624-1100 (phone_number) — Business Phone
FAQ
What were Rigel Pharmaceuticals' total revenues for the first quarter of 2025?
The filing does not explicitly state total revenues for Q1 2025 in the provided snippet, but it does list line items related to chargebacks, discounts, fees, and rebates for the periods ending March 31, 2025, and March 31, 2024.
What is the company's fiscal year end?
Rigel Pharmaceuticals' fiscal year ends on December 31.
What is the filing date of this 10-Q report?
This 10-Q report was filed on May 6, 2025.
What is the primary business address of Rigel Pharmaceuticals?
The primary business address is 611 Gateway Boulevard, Suite 900, South San Francisco, CA 94080.
What is the SIC code for Rigel Pharmaceuticals?
The Standard Industrial Classification (SIC) code for Rigel Pharmaceuticals is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 6, 2025 regarding RIGEL PHARMACEUTICALS INC (RIGL).